128 related articles for article (PubMed ID: 10334666)
21. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.
Jungers P; Choukroun G; Oualim Z; Robino C; Nguyen AT; Man NK
Nephrol Dial Transplant; 2001 Feb; 16(2):307-12. PubMed ID: 11158405
[TBL] [Abstract][Full Text] [Related]
22. Higher target haemoglobin level and early anaemia treatment: different or complementary concepts?
Macdougall LC
Nephrol Dial Transplant; 2000; 15 Suppl 3():3-7. PubMed ID: 11032350
[TBL] [Abstract][Full Text] [Related]
23. Non-erythropoietin-based anaemia management in chronic kidney disease.
Hörl WH
Nephrol Dial Transplant; 2002; 17 Suppl 11():35-8. PubMed ID: 12386256
[TBL] [Abstract][Full Text] [Related]
24. How should we manage anaemia in patients with diabetes?
Dikow R; Schwenger V; Schömig M; Ritz E
Nephrol Dial Transplant; 2002; 17 Suppl 1():67-72. PubMed ID: 11812916
[TBL] [Abstract][Full Text] [Related]
25. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.
Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Osterborg A; Repetto L; Soubeyran P;
Eur J Cancer; 2007 Jan; 43(2):258-70. PubMed ID: 17182241
[TBL] [Abstract][Full Text] [Related]
26. Epoetin in cancer-related anaemia.
Ludwig H
Nephrol Dial Transplant; 1999; 14 Suppl 2():85-92. PubMed ID: 10334673
[TBL] [Abstract][Full Text] [Related]
27. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
Jacobs C; Frei D; Perkins AC
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
[TBL] [Abstract][Full Text] [Related]
28. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin.
Hörl WH; Vanrenterghem Y; Canaud B; Mann J; Teatini U; Wanner C; Wikström B
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii25-32. PubMed ID: 15824127
[TBL] [Abstract][Full Text] [Related]
29. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
30. Fluctuations in haemoglobin levels in haemodialysis, pre-dialysis and peritoneal dialysis patients receiving epoetin alpha or darbepoetin alpha.
Walker R; Pussell BA;
Nephrology (Carlton); 2009 Oct; 14(7):689-95. PubMed ID: 19796029
[TBL] [Abstract][Full Text] [Related]
31. Anaemia management in chronic kidney disease patients: an overview of current clinical practice.
Valderrábano F
Nephrol Dial Transplant; 2002; 17 Suppl 1():13-8. PubMed ID: 11812907
[TBL] [Abstract][Full Text] [Related]
32. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients.
Kwan JT; Pratt RD;
Curr Med Res Opin; 2007 Feb; 23(2):307-11. PubMed ID: 17288685
[TBL] [Abstract][Full Text] [Related]
33. The CREATE trial--building the evidence.
Eckardt KU;
Nephrol Dial Transplant; 2001; 16 Suppl 2():16-8. PubMed ID: 11369844
[TBL] [Abstract][Full Text] [Related]
34. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta.
Bock HA; Hirt-Minkowski P; Brünisholz M; Keusch G; Rey S; von Albertini B;
Nephrol Dial Transplant; 2008 Jan; 23(1):301-8. PubMed ID: 17890745
[TBL] [Abstract][Full Text] [Related]
35. A risk-benefit assessment of epoetin in the management of anaemia associated with cancer.
Beguin Y
Drug Saf; 1998 Oct; 19(4):269-82. PubMed ID: 9804442
[TBL] [Abstract][Full Text] [Related]
36. Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer.
Cheer SM; Wagstaff AJ
Drugs; 2004; 64(3):323-46. PubMed ID: 14871172
[TBL] [Abstract][Full Text] [Related]
37. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
38. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
Servilla KS; Singh AK; Hunt WC; Harford AM; Miskulin D; Meyer KB; Bedrick EJ; Rohrscheib MR; Tzamaloukas AH; Johnson HK; Zager PG
Am J Kidney Dis; 2009 Sep; 54(3):498-510. PubMed ID: 19628315
[TBL] [Abstract][Full Text] [Related]
39. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron.
Silverberg DS; Wexler D; Blum M; Tchebiner JZ; Sheps D; Keren G; Schwartz D; Baruch R; Yachnin T; Shaked M; Schwartz I; Steinbruch S; Iaina A
Nephrol Dial Transplant; 2003 Jan; 18(1):141-6. PubMed ID: 12480972
[TBL] [Abstract][Full Text] [Related]
40. Anaemia, diabetes and chronic kidney disease: where are we now?
Stevens PE
J Ren Care; 2012 Feb; 38 Suppl 1():67-77. PubMed ID: 22348366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
